First entirely digital clinical trial encourages physical activity

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study. The finding comes by way of the first-ever entirely digital, randomized clinical trial, which sought to answer two overarching questions: Is it feasible to successfully run an entirely digital, randomized clinical trial? And is it possible to encourage people to exercise more by using a smartphone app?

The study, overseen by Euan Ashley, MBChB, DPhil, professor of medicine, of genetics and of biomedical data science at Stanford, shows that the answer to both questions is yes.

Ashley and his colleagues conducted a clinical trial using MyHeart Counts, an app he and other scientists at Stanford developed using Apple's ResearchKit platform. The app, which was first deployed on smartphones in 2015, was launched to help track physical activity and other heart-related information, such as heart rate. Now, it's the main tool for a full-on randomized clinical trial, including patient recruitment, consent and interventions. It also returns data to participants.

"In this digital era, we have to think of ways to engage people in their health," he said. "The number of smartphone users these days is huge, and using an app to host the trial lets us tap into that population. If people are addicted to their phones, maybe we can also get them addicted to their health."

On a weekly, rotating basis, the digital trial "prescribed" one of four simple interventions for each participant enrolled in MyHeart Counts -- things like reminders to walk more or stand up. In the end, the prompts worked, although modestly so. Regardless of the type of intervention, Ashley and his team saw about a 10% increase in activity compared to the participants' baselines.

A paper detailing the findings of this study will publish online Oct. 9 in The Lancet Digital Health. Ashley is the senior author of the study. Lead authorship is shared by Stanford graduate student Anna Shcherbina and Steven Hershman, PhD, director of Stanford's mHealth in cardiovascular medicine.

Mobile motivation

About a year after the launch of the MyHeart Counts app, Ashley opened up enrollment for the clinical trial. Over about 18 months, 1075 participants enrolled and completed at least one intervention, and 493 completed the entire trial.

An 80% dropout rate would spell the end of most trials, but not in this one. "In the digital world, there's quite a low bar for entry -- you can sign up while you're standing in line for coffee -- so there's a low bar for exiting a trial too," Ashley said. A clinical trial of 100 people is considered normal, if not large, and even with the high dropout rate, the MyHeart Counts digital clinical trial ended up with about five times that number.

During the first week of the trial, participants lived their lives without extra instruction from the app. In this way, they established their own baseline and served as their own control. After the initial week, each participant was randomly assigned to one of four different "soft-touch" interventions: encouragement to take more steps; hourly reminders to stand up; instructions to read health guidelines from the American Heart Association; or personalized "e-coaching" that sent a daily message to participants based on their routine activities. Those who reported a more sedentary lifestyle might receive a message prompting a Sunday morning walk, while those who are naturally more active might receive encouragement to keep up consistent physical activity. Every week, participants completed a new intervention until they'd experienced all four.

Across almost 500 participants, the bump in activity -- measured through step count -- was modest -- a 10% increase -- but still statistically significant. "Sure, we would have rather seen a 300% increase, but with the light-touch interventions that we chose, it was probably never realistic to expect those numbers," Ashley said. "But the main takeaway is that at end of the day, we find that there's a real, small positive effect from these interventions." And, he said, the study also serves as a template for all-digital randomized clinical trials in the future.

A trend toward digital

Now, Ashley and his colleagues want to investigate further. In their next trial, they plan to ask more nuanced questions: How long do the participants keep up the extra steps? And, is it possible to enhance the results by either increasing the intensity of the intervention, tailoring the intervention to a person's specific motivations, or lengthening the duration of the trial?

Down the line, Ashley sees value in personalizing the interventions more to an individual's motivations and goals. "We don't want to make it too complicated. And we aren't ignoring the fact that even a single simple prompt did increase steps," he said. "But different things motivate different people, and if we can play to that, it may help participants reach a new level of activity."

Outside of future MyHeart Counts trials, Ashley and his team are starting to partner with other scientists to help them carry out their own digital clinical trials in areas such as heart transplant recovery and pulmonary hypertension. "Digital platforms allow us to connect directly to the patients in a way that's more immediate and more extensive," Ashley said. "And I think this type of more direct sensor-based measurement can not only help patients enhance their own health, but help doctors notice health issues early on and address them sooner."

Anna Shcherbina, Steven G Hershman, Laura Lazzeroni, Abby C King, Jack W O'Sullivan, Eric Hekler, Yasbanoo Moayedi, Aleksandra Pavlovic, Daryl Waggott, Abhinav Sharma, Alan Yeung, Jeffrey W Christle, Matthew T Wheeler, Michael V McConnell, Robert A Harrington, Euan A Ashley.
The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study.
The Lancet Digital Health, October 9, 2019. doi: 10.1016/S2589-7500(19)30129-3.

News article by Hanae Armitage, Office of Communications, Stanford Medicine.

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...